Imaging HER2-low breast cancers using a specialized PET scan

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the diagnostic potential of a new imaging technique that utilizes a radiolabeled version of the anti-HER2 antibody trastuzumab to detect HER2-low expressing breast cancers. The approach combines this imaging with existing FDG PET scans to improve the identification of metastatic breast cancer cases that may have previously been classified as HER2-negative. By focusing on HER2-low status, which has gained relevance due to recent advancements in immunotherapy, the study seeks to enhance the accuracy of cancer detection and treatment planning. Participants will undergo PET imaging with 89Zr-trastuzumab to assess its effectiveness in identifying these cancers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* HER2-low metastatic breast cancer;
* At least 18 years-old ;
* Able to stay in supine position for at least 30 minutes;
* Written inform consent.

Exclusion Criteria:

* Pregnancy or concomitant breast feeding;
* Hepatic disorders such as cirrhosis, hepatitis, or any other liver condition judged as significant by the treating physician and that could impair the biliary excretion of 89Zr-trastuzumab;
* Renal disorders considered significant by the treating physician and that could impair the normal elimination of 89Zr-trastuzumab;
* Known hypersensitivity or allergy to trastuzumab, desferrioxamine, or any constituents of 89Zr-trastuzumab.

Where it's running

• Centre de recherche du CHUS
  Sherbrooke, Quebec, Canada Recruiting

Study contacts

• Principal investigator: Éric E Turcotte, MD, FRCPC — Université de Sherbrooke
• Study coordinator: Michel Paquette, PhD
• Email: michel.paquette@usherbrooke.ca
• Phone: 819-346-1110

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evorpacept plus trastuzumab and chemotherapy for metastatic HER2‑positive breast cancer after trastuzumab‑deruxtecan

  This trial will test whether adding evorpacept to trastuzumab and chemotherapy helps people with metastatic HER2‑positive breast cancer whose disease progressed after trastuzumab‑deruxtecan.

  Recruiting at 60 sites Phase 2 ALX Oncology Inc. · Phoenix, Arizona and 60 other locations · NCT07007559

• Testing a new drug for patients with metastatic HER2-negative breast cancer

  This study is testing a new drug called T-DXd to see if it can help adults with metastatic HER2-negative breast cancer feel better and improve their treatment outcomes.

  Recruiting at 3 sites Phase 2 Yale University · New Haven, Connecticut and 2 other locations · NCT06750484

• Detecting Tumor DNA in Blood to Find T-DXd Candidates in HR+/HER2-Low Metastatic Breast Cancer

  We test whether persistent tumor DNA in blood after starting standard therapy can identify HR+ HER2-low metastatic breast cancer patients who may benefit from trastuzumab deruxtecan.

  Recruiting at 12 sites Phase 2 Unicancer · Amiens and 39 other locations · NCT06680596

• Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer

  This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gang-Nam · NCT07911280

• Neoadjuvant Pyrotinib-to-pertuzumab for HER2-positive early breast cancer

  This trial tests whether a two-step neoadjuvant plan with Pyrotinib plus Trastuzumab and Docetaxel followed by Pertuzumab plus Trastuzumab and Docetaxel works better than four cycles of Pertuzumab plus Trastuzumab and Docetaxel in women with HER2-positive early- to locally advanced breast cancer.

  Recruiting Phase 3 Shanghai Jiao Tong University School of Medicine · Shanghai · NCT07797218

• Trastuzumab Rezetecan and Gemcitabine before surgery for HER2-positive UTUC

  This study tests whether giving trastuzumab deruxtecan with gemcitabine before and around surgery can improve outcomes for people with HER2-positive upper tract urothelial cancer.

  Recruiting at 10 sites Phase 2 Tongji Hospital · Huanggang, Hubei and 9 other locations · NCT07741448

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.